Eli Lilly and Company completed its acquisition of Ventyx Biosciences, Inc. on 2026-03-04, according to the Form 8-K Ventyx Biosciences, Inc. filed with the SEC on 2026-03-04. The filing states a price of $1.2 billion. Ventyx Biosciences, Inc. filed the report because the deal made it part of Eli Lilly and Company.
| Acquirer | Eli Lilly and Company |
|---|---|
| Acquired | Ventyx Biosciences, Inc. |
| Completed | 2026-03-04 |
| Price stated in the filing | $1.2 billion |
| Reported by | Ventyx Biosciences, Inc. (VTYX), the company acquired |
| Filing | Form 8-K, filed 2026-03-04 |
Want the whole picture on Eli Lilly and Company?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Eli Lilly and Company: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Eli Lilly and Company covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
On March 4, 2026 (the "Closing Date"), pursuant to the Merger Agreement, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent.
The price, in the filing's words
The aggregate consideration that was or will be paid to stockholders and other equity holders of the Company in connection with the Merger is approximately $1.2 billion, without giving effect to related transaction fees and expenses.
More from the filing
As previously disclosed in the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC") on January 7, 2026, Ventyx Biosciences, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement"), dated January 7, 2026, with Eli Lilly and Company, an Indiana corporation ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation, a Delaware corporation ("Merger Sub").
Capitalized terms used herein and not otherwise defined herein have the meanings set forth in the Merger Agreement.
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, at the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Common Stock") issued and outstanding immediately prior to the Effective Time, was converted into the right to receive $14.00 per share, payable to the holder in cash, without interest (the "Common Merger Consideration Amount") and less any applicable tax withholding.
Quoted from Ventyx Biosciences, Inc.'s Form 8-K.
Other acquisitions by Eli Lilly and Company
| Completed | Acquired | Price stated |
|---|---|---|
| 2025-11-07 | Adverum Biotechnologies, Inc. | Not stated |
| 2026-09-11 | AtaiBeckley Inc. | Not stated |
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Eli Lilly and CompanyLook up Eli Lilly and Company and see what is on record before you decide.
Get the free SnapshotWhere this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.